Mitoquinol mesylate

CAS No. 845959-55-9

Mitoquinol mesylate( —— )

Catalog No. M33808 CAS No. 845959-55-9

Mitoquinol, a ubiquinone derivative, specifically accumulates in mitochondria due to the covalent attachment of the cation triphenylphosphonium.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 126 Get Quote
5MG 255 Get Quote
10MG 466 Get Quote
25MG 845 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Mitoquinol mesylate
  • Note
    Research use only, not for human use.
  • Brief Description
    Mitoquinol, a ubiquinone derivative, specifically accumulates in mitochondria due to the covalent attachment of the cation triphenylphosphonium.
  • Description
    Mitoquinol, a ubiquinone derivative, specifically accumulates in mitochondria due to the covalent attachment of the cation triphenylphosphonium. Mitoquinol is an antioxidant, protecting mitochondria from oxidative damage and preventing lipid peroxidation-induced apoptosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    845959-55-9
  • Formula Weight
    680.84
  • Molecular Formula
    C38H49O7PS
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CS([O-])(=O)=O.COc1c(O)c(C)c(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)c(O)c1OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Spiroplatin

    Spiroplatin (TNO-6) is a novel platinum-containing analogue with antitumor activity that is commonly used in the study of solid tumors.

  • Lefradafiban

    Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

  • Teriflunomide(b)

    Teriflunomide is the principal active metabolite of leflunomide?an approved therapy for rheumatoid arthritis and?multiple sclerosis.